Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
Source : https://ascopubs.org/doi/10.1200/JCO.21.02677
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence...
Relevance: Although exploratory analyses suggested similar HRs in favor of abemaciclib regardless of Ki-67 status, there were relatively few Ki-67 low tumors in monarchE. When discussing treatment options with patients, the potential benefits (improved IDFS) should be weighed against the potential harms (treatment toxicity and financial cost).
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34930649/
CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression...
Conclusion/Relevance: In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility. Studies conducted in the neoadjuvant setting might help to explain the...
Risk Factors, Prognostic Factors, and Nomogram for Distant Metastasis in Breast Cancer Patients Without Lymph Node Metastasis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653828/
Yu Min, ‡ Xiaoman Liu, ‡ Daixing Hu, Hang Chen, Jialin Chen, Ke Xiang, Guobing Yin, Yuling Han, Yang Feng, * , † and Haojun Luo * , † Keywords:...
Conclusion: The clinicopathological characteristics associated with the risk of DM and the prognosis of female breast cancer patients without lymph node metastasis but with DM are determined. A novel nomogram for predicting 1-, 3-, 5- year CSS in T1-3N0M1 patients is also well established and validated, which could help clinicians better...
Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34899904/
PSCC of the breast after radical surgery has a poor prognosis. Adjuvant RT after LUMP significantly improves survival of patients with PSCC of the breast. Further studies are still needed...
Conclusion: PSCC of the breast after radical surgery has a poor prognosis. Adjuvant RT after LUMP significantly improves survival of patients with PSCC of the breast. Further studies are still needed to investigate the role of adjuvant RT in PSCC of the breast after mastectomy.
Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27
Source : https://www.tandfonline.com/doi/full/10.1080/15384101.2021.1984663
Cyclin-dependent kinase 4 (CDK4) is a master integrator that couples mitogenic/oncogenic signaling with the cell division cycle. It is deregulated in most cancers and inhibitors of CDK4 have become...
Conclusions: These monoclonal antibodies specifically recognize T172-phosphorylated CDK4 in a variety of assays, including western blotting, immunoprecipitation and, as a capture antibody, a sensitive ELISA from cell lysates. The specific immunoprecipitation of T172-phosphorylated CDK4 allowed to clarify the involvement of phosphorylations of...